Pharmacokinetic Comparison of Multiple Formulations of Topiramate and Phentermine in Obese Adults
Completed
VIVUS, Inc.
Phase 1
2007-07-01
The primary objective of this study is to describe the single- and multiple-dose
pharmacokinetic profiles of two novel formulations of topiramate and commercially available
immediate release topiramate, all dosed with immediate release phentermine.
A Study Comparing Multiple Doses of VI-0521 With Placebo and Their Single-agent Constituents for Treatment of Obesity in Adults
Completed
Medpace, Inc.
Phase 3
2007-12-01
The objective of this study is to evaluate the safety and efficacy of various doses of
VI-0521 compared to both placebo, and the single-agent components that comprise each
combination dose. This study will provide confirmatory data to demonstrate that doses of
VI-0521 have efficacy that is greater than placebo and each of the single-agent components
that comprise the combination dose.
A Study Comparing Multiple Doses of VI-0521 With Placebo and Their Single-agent Constituents for Treatment of Obesity in Adults
Completed
VIVUS, Inc.
Phase 3
2007-12-01
The objective of this study is to evaluate the safety and efficacy of various doses of
VI-0521 compared to both placebo, and the single-agent components that comprise each
combination dose. This study will provide confirmatory data to demonstrate that doses of
VI-0521 have efficacy that is greater than placebo and each of the single-agent components
that comprise the combination dose.
A VI-0521 Study to Evaluate the Long-term Safety and Efficacy in Type 2 Diabetic Adults
Completed
Sentrx
Phase 2
2008-01-01
The purpose of the study is to determine the long-term safety and efficacy of VI-0521
(phentermine/topiramate) compared to placebo in providing blood sugar control in Type 2
diabetic adults. Continuation of initial 6 month trial.
A VI-0521 Study to Evaluate the Long-term Safety and Efficacy in Type 2 Diabetic Adults
Completed
Synteract, Inc.
Phase 2
2008-01-01
The purpose of the study is to determine the long-term safety and efficacy of VI-0521
(phentermine/topiramate) compared to placebo in providing blood sugar control in Type 2
diabetic adults. Continuation of initial 6 month trial.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
